Real-world use of glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes: A retrospective database study (DEFINE-G)
Authors' conclusion
This study shows increased GLP-1RA prescriptions over 5 years. HbA1c and BW reduced 6 months after GLP-1RA initiation in patients with T2D in a Japanese real-world setting.
Study context
- Population
- Japanese patients with T2D receiving GLP-1 RAs, 2016–2020, J-DREAMS databaseGLP-1RA-naïve
- Participants
- 569 patients
- Outcome
- Changes in HbA1c, body weight, BMI and proportion reaching HbA1c targets in GLP-1RA-naïve patients
- Follow-up
- 6-24 months after GLP-1RA initiation
Methodological detailsreal-world, J-DREAMS database
- Real-world
- J-DREAMS database
Main finding
As reported in the abstract
Change in HbA1c · 6 months after treatment initiation
HbA1c change (95% CI −0.7, −0.5); stabilised until 24 months; P < 0.001
-0.6%
HbA1c change, mmol/mol
−6 mmol/mol
95% CI −7, −5
Observational data: associations, not effects.
Further findings
Mean body weight (BW) change · 6 months
- Mean BW change (95% CI −1.31, −0.80); P < 0.001
- −1.05 kg
Mean body mass index (BMI) change · 6 months
- Mean BMI change (95% CI −0.53, −0.32); P < 0.001
- −0.43 kg/m²
HbA1c targets · 6 months
- HbA1c < 7.0% (<53 mmol/mol), increase from
- 16% to 27%
- HbA1c <8.0% (<64 mmol/mol), increase from
- 43% to 65%
- HbA1c reduction ≥1.0% (≥11 mmol/mol); P < 0.001
- 33%
Proportion of patients with GLP-1RA prescriptions · 2016-2020
- Increase in proportion with GLP-1RA prescriptions
- 3.6% to 9.6%
Original publication
Real-world use of glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes: A retrospective database study (DEFINE-G). Diabetes Res Clin Pract. Published 21 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →